Akums Drugs and Pharmaceuticals Limited has secured a strategic agreement with a leading global pharmaceutical company for the manufacture and supply of oral liquid formulations in the European market. This collaboration marks a significant milestone in Akums’ growth strategy as it expands its presence in Europe and other regulated markets.
The agreement covers the production and supply of multiple SKUs of oral liquid formulations, set to be marketed across several European countries. Commercial supply will begin in 2027 and continue through 2032. Akums will also initiate the European approval process for its oral liquid manufacturing site, which is expected to be completed by 2026. This new approval will complement Akums’ existing European certifications for two other sites (Injectables and Oral Solids).
The total value of the agreement is approximately EUR 200 million (INR 1,760 crores), with Akums receiving an upfront payment of EUR 100 million (INR 880 crores) for product development and regulatory site approvals.
This partnership positions Akums as a key player in the European pharmaceutical market, further strengthening its global footprint and commitment to delivering high-quality, regulatory-compliant products worldwide.
In the meantime, Akums Drugs’ shares opened at ₹598.00, with a daily high of ₹626.00 and a low of ₹590.20. Over the past year, the stock has fluctuated significantly, marking a 52-week high of ₹1,175.90 and a low of ₹530.05.
